Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesothelioma
A drug that made its mark in breast cancer showed preliminary activity in its first-ever…
Browsing Tag
CDK46
Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast Cancer
Adding a CDK4/6 inhibitor to adjuvant endocrine therapy significantly improved invasive…
First CDK4/6 inhibitor OK’d for Early, High-Risk Breast Cancer
The FDA approved the CDK4/6 inhibitor abemaciclib (Verzenio), in combination with standard…
Studies Confirm OS Benefit With CDK4/6 Inhibitors in Advanced Breast Cancer
Two studies reported at the recent virtual American Society of Clinical Oncology (ASCO) annual meeting showed…